Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-19

May need to really start questioning the validity of this IP as World class; imo, is this a actual product yet or still a concept that needs to be much developed until such time it is a ‘product’, I imagine it is definitely the latter, happy to be corrected.

A World class product that has had no formal offers to acquire and a sp that hardly classes this IP as such beggars the question of WHY.

All its ‘good’ points, current IP, have been well highlighted, what are its ‘weak’ points?, …. on successful commercialisation will it be a ‘rainmaker’ for the Company?, the obvious answer of ‘yes’ hardly accounts for the current sp and lack of suitors or white angels coming to the rescue.

Very pertinent questions; the costings for the next four years plus,; the R&D costings and the associated operational costs are what?, and WILL this IP be disruptive or on par with the CardioCel IP, Company saviour yet not a Company ‘maker’, huge bias here, imo, to it being a Company maker, maybe, but not yet reflected in any form in the interim.

Not sure of the logic in your second sentence cgt, what actual leverage does Anteris actually have?, the sp and past history would suggest very little.

Financial governance has been poor, next to zero projections by the Company have materialised, all the way from ‘’No more CRs’ talk to the present date, and a market sentiment that reflects that as such. Ugly reality may be that the above is very relevant and the causation accounting for the poor financial governance.

Going it alone…. doubt if the Company would ever announce that (!), certainly would be far from ideal, reality may be that the Company will have to make some heavy concessions to any future partner that is willing to provide a ‘blank’ cheque.

Never has so much been promised and so little delivered.

Imho, not advice.